Literature DB >> 30190917

Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy.

Cesar E Ochoa1, Richard W Joseph1.   

Abstract

Entities:  

Keywords:  anti-CTLA-4; anti-PD-1; immunotherapy; ipilimumab; metastatic melanoma; nivolumab; pembrolizumab

Year:  2017        PMID： 30190917      PMCID： PMC6094594          DOI： 10.2217/mmt-2017-0010

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  12 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 2.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

3.  Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Authors:  Lisa Zimmer; Susmitha Apuri; Zeynep Eroglu; Lisa A Kottschade; Andrea Forschner; Ralf Gutzmer; Max Schlaak; Lucie Heinzerling; Angela M Krackhardt; Carmen Loquai; Svetomir N Markovic; Richard W Joseph; Kelly Markey; Jochen S Utikal; Carsten Weishaupt; Simone M Goldinger; Vernon K Sondak; Jonathan S Zager; Dirk Schadendorf; Nikhil I Khushalani
Journal:  Eur J Cancer       Date:  2017-02-17       Impact factor: 9.162

4.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

5.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Authors:  Jeffrey S Weber; Sandra P D'Angelo; David Minor; F Stephen Hodi; Ralf Gutzmer; Bart Neyns; Christoph Hoeller; Nikhil I Khushalani; Wilson H Miller; Christopher D Lao; Gerald P Linette; Luc Thomas; Paul Lorigan; Kenneth F Grossmann; Jessica C Hassel; Michele Maio; Mario Sznol; Paolo A Ascierto; Peter Mohr; Bartosz Chmielowski; Alan Bryce; Inge M Svane; Jean-Jacques Grob; Angela M Krackhardt; Christine Horak; Alexandre Lambert; Arvin S Yang; James Larkin
Journal:  Lancet Oncol       Date:  2015-03-18       Impact factor: 41.316

6.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

7.  Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.

Authors:  Aurélie Jacobsoone-Ulrich; Philippe Jamme; Salim Alkeraye; Véronique Dzwiniel; Emmanuel Faure; Carole Templier; Laurent Mortier
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

8.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

9.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Authors:  Antoni Ribas; Igor Puzanov; Reinhard Dummer; Dirk Schadendorf; Omid Hamid; Caroline Robert; F Stephen Hodi; Jacob Schachter; Anna C Pavlick; Karl D Lewis; Lee D Cranmer; Christian U Blank; Steven J O'Day; Paolo A Ascierto; April K S Salama; Kim A Margolin; Carmen Loquai; Thomas K Eigentler; Tara C Gangadhar; Matteo S Carlino; Sanjiv S Agarwala; Stergios J Moschos; Jeffrey A Sosman; Simone M Goldinger; Ronnie Shapira-Frommer; Rene Gonzalez; John M Kirkwood; Jedd D Wolchok; Alexander Eggermont; Xiaoyun Nicole Li; Wei Zhou; Adriane M Zernhelt; Joy Lis; Scot Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet Oncol       Date:  2015-06-23       Impact factor: 41.316

10.  Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.

Authors:  S Bowyer; P Prithviraj; P Lorigan; J Larkin; G McArthur; V Atkinson; M Millward; M Khou; S Diem; S Ramanujam; B Kong; E Liniker; A Guminski; P Parente; M C Andrews; S Parakh; J Cebon; G V Long; M S Carlino; O Klein
Journal:  Br J Cancer       Date:  2016-04-28       Impact factor: 7.640
View more
  5 in total

Review 1.  Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma.

Authors:  Francesca Aroldi; Mark R Middleton
Journal:  Am J Clin Dermatol       Date:  2022-03-31       Impact factor: 7.403

Review 2.  Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need.

Authors:  F Serra; S Barruscotti; T Dominioni; A Zuccarini; P Pedrazzoli; S Chiellino
Journal:  Curr Oncol Rep       Date:  2021-05-19       Impact factor: 5.075

3.  PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide.

Authors:  Tiesuo Zhao; Tian Wei; Jing Guo; Yangeng Wang; Xiangyi Shi; Sheng Guo; Xiaolong Jia; Huijie Jia; Zhiwei Feng
Journal:  Cell Death Dis       Date:  2019-02-18       Impact factor: 8.469

4.  Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination.

Authors:  Wouter W van Willigen; Martine Bloemendal; Marye J Boers-Sonderen; Jan Willem B de Groot; Rutger H T Koornstra; Astrid A M van der Veldt; John B A G Haanen; Steve Boudewijns; Gerty Schreibelt; Winald R Gerritsen; I Jolanda M de Vries; Kalijn F Bol
Journal:  Oncoimmunology       Date:  2020-03-22       Impact factor: 8.110

5.  A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.

Authors:  Craig L Slingluff; Hassane M Zarour; Hussein Abdul-Hassan Tawbi; John M Kirkwood; Michael A Postow; Philip Friedlander; Craig E Devoe; Elizabeth M Gaughan; Ileana S Mauldin; Walter C Olson; Kelly T Smith; Mary J Macri; Toni Ricciardi; Aileen Ryan; Ralph Venhaus; Jedd D Wolchok
Journal:  Oncoimmunology       Date:  2021-03-26       Impact factor: 8.110
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.